CRANBURY, N.J., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced updated details on patients screened for one of the global Phase 3 registration studies (Study 011) to investigate the pharmacological chaperone migalastat HCl for Fabry disease. These results were presented in a poster1 at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2012 (SSIEM 2012).
